Archived Facts

Pervasis Provides Update On Progress Of Clinical Program Targeting Peripheral Arterial Disease
Pervasis Therapeutics announced that the first cohort of patients has been fully enrolled in the Phase 1/2 clinical study of PVS-10200, an investigational new drug under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery. Initial study results from this patient cohort are expected …

Read more on Medical News Today

Popular Posts:

Related Posts:

Leave a Reply